November 1, 2011
Dainippon Sumitomo Pharma (DSP) reported a 5.6% decline in consolidated sales compared the corresponding period of the previous year in its first-half settlement of accounts for April-September 2011. Despite contributions from products including the hypertension treatment Avapro (irbesartan) and the...read more